Brief: Aptose Biosciences- Luxeptinib Preclinical Data Extend Potential Applications From Oncology To Inflammation
02/05/2022 21:43
May 2 (Reuters) - Aptose Biosciences Inc APS.TO :
* LUXEPTINIB PRECLINICAL DATA EXTEND POTENTIAL APPLICATIONS
FROM
ONCOLOGY TO INFLAMMATION
Source text for Eikon: ID:nGNX2gVct9
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting